Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Clover Health Investments Corp.'s CEO of Medicare Advantage, Jamie L. Reynoso, sold 4,913 shares of Class A Common Stock for a weighted average price of $2.61 per share.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp., reported a sale of company stock.
• The transaction involved the disposition of 4,913 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $2.61 per share, with prices ranging from $2.58 to $2.64.
• The sale was executed on December 18, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Reynoso on March 13, 2025.
• Following the sale, Reynoso beneficially owns 2,767,240 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: A neutral score as this is a routine insider transaction under a pre-arranged plan, which is not inherently positive or negative for the company's operational performance, though insider sales can sometimes be viewed with slight caution by investors.

Negatives

• An insider sale by a key executive, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

This transaction is a routine insider trading disclosure for an executive at a healthcare technology company operating in the Medicare Advantage sector. It does not inherently reflect broader industry trends but is a standard compliance filing.

Stakeholder Impact

• Shareholders may note the reduction in direct equity ownership by a key executive, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic timing.

Key Dates

Recommendation

This Form 4 reports a routine insider sale under a pre-arranged 10b5-1 plan. Such transactions are typically not indicative of a change in the company's fundamental outlook or performance. Therefore, it does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Clover Health, CLOV, Insider Sale, Form 4, Jamie L. Reynoso, Stock Transaction, 10b5-1 Plan, Medicare Advantage